Quantiferon TB Gold: Nursing Guide
QuantiFERON-TB Gold Plus is an interferon-gamma release assay (IGRA) — a TB blood test that detects immune sensitization to Mycobacterium tuberculosis antigens without the return visit required for a tuberculin skin test. Nurses protect patients when special collection tubes are filled, mixed, and incubated on time, when a positive result is not treated as active TB disease alone, and when cough, fever, or night sweats prompt airborne precautions and further workup per protocol.
Contents
Quick Facts
Key Takeaway
A QuantiFERON-TB Gold result tells you whether the immune system has been sensitized to TB bacteria — it does not by itself prove active pulmonary disease or clear a patient for high-risk.
Specimen & Collection Details
Nurse quick-reference for collection prep that affects result quality.
QuantiFERON-TB Gold Plus kit tubes (gray Nil, green TB antigen, lime Mitogen — cap colours vary by kit version; follow institutional kit insert)
Manufacturer-dried antigens and controls inside specialized blood collection tubes — not standard EDTA or serum tubes; always use the laboratory-issued QuantiFERON kit
Whole blood in QuantiFERON-TB Gold Plus collection tubes (Nil, TB antigen, Mitogen — kit per laboratory)
Typically 1 mL whole blood per tube filled to the kit indicator line (approximately 0.8–1.2 mL per manufacturer instructions reviewed for QuantiFERON-TB Gold Plus)
Single-visit blood draw when ordered; tubes must reach 37°C incubation within the time window specified in the kit insert and local laboratory protocol (commonly within 16 hours of collection per manufacturer instructions reviewed)
No special preparation is usually required for IGRA blood testing, but nurses should follow local policy and the ordering clinician’s instructions
Maintain tubes at room temperature (approximately 17–25°C per manufacturer kit instructions) until incubation; shake or invert tubes per kit insert immediately after draw and again before incubation if not incubated immediately; transport incubated or pre-incubation specimens per reporting laboratory requirements
Final IGRA results often return within one to three business days after valid laboratory processing — not specified as a single universal interval in the published references
Outpatient clinic, employee health, prenatal or immigration screening, rheumatology or biologic-medication clinics, hospital laboratory, or public health TB program per setting
What is Quantiferon TB Gold?
Quantiferon TB Gold is an interferon-gamma release assay (IGRA) — a TB blood test that measures how T cells in whole blood release interferon-gamma after exposure to M. tuberculosis-specific antigens in specialized collection tubes. QuantiFERON-TB Gold Plus (the current generation in many laboratories) uses multiple tubes including nil (negative control), TB antigen, and mitogen (positive control) tubes. The laboratory incubates tubes, harvests plasma, and reports a qualitative result used to detect TB infection, especially latent TB infection (LTBI), and to support evaluation when active TB is suspected.
Overview
Nurses order or collect QuantiFERON-TB Gold testing when clinicians screen for tuberculosis infection before adalimumab or other immunosuppressive therapy, during employee or immigration health clearance, after TB exposure, in prenatal care, or when symptoms such as persistent cough or fever raise concern. Unlike the intradermal tuberculin skin test, IGRA requires only one visit for blood collection but demands strict pre-analytic handling of kit tubes.
public health guidance and standard clinical references emphasize that IGRA detects TB infection but does not distinguish latent infection from active TB disease by itself. A positive result requires clinical assessment and often chest radiography, symptom review, and sometimes sputum or other cultures per prescriber and public health guidance. IGRA is generally less affected by BCG vaccination than the skin test, but immunosuppression and some acute illnesses can yield false-negative or indeterminate results — nurses document risk context and avoid telling patients a negative result clears all TB concern when symptoms persist.
Before draw: confirm QuantiFERON kit is available, verify two identifiers, and review immunosuppressive medicines and recent TB exposure. After collection: document tube fill, mixing, incubation handoff, and transport time. When results return: notify the prescriber of positive or indeterminate IGRA per protocol; initiate airborne isolation and further workup when active TB is suspected; support isoniazid or other LTBI treatment teaching only per the authorized care plan — do not start or stop TB medicines independently.
LTBI Misinterpretation and Airborne Precaution Safety
QuantiFERON-TB Gold results change infection-control and immunotherapy decisions — yet a positive IGRA is not a bedside diagnosis of contagious active TB, and a negative IGRA on an invalid specimen can falsely reassure. Nurses prevent harm by protecting tube validity, correcting misinformation before biologics, and escalating when cough, fever, or hypoxemia suggests pulmonary disease.
- Positive IGRA with respiratory symptoms and chest imaging not yet reviewed
- Biologic or high-dose immunosuppression scheduled with positive or indeterminate IGRA and no TB evaluation
- Underfilled kit tubes, missed incubation window, or laboratory rejection with ongoing TB suspicion
- Patient told a positive IGRA automatically clears same-day infusion or requires no follow-up
Document: tube fill and mixing, incubation handoff, qualitative result, symptoms, prescriber and public health notification, isolation orders when indicated, and evaluate outcomes after imaging and consult recommendations.
What QuantiFERON-TB Gold Can and Cannot Tell You
This test can help identify:
- M. tuberculosis infection (immune sensitization) on a valid IGRA specimen
- Need for LTBI treatment evaluation or active TB workup after a positive result
- TB infection status when BCG history makes tuberculin skin test interpretation difficult
- Pre-biologic or employee-health screening with a single blood-draw visit
This test cannot:
- Distinguish latent TB infection from active TB disease by itself per public health guidance and standard clinical references
- Prove current infectiousness or replace airborne precautions when active pulmonary TB is suspected
- Rule out TB in severely immunocompromised patients when clinical suspicion remains high
- Monitor treatment response as a routine serial marker unless specifically ordered and interpreted by clinicians
Pre-draw Checks for IGRA Blood Collection Tubes
Verify
Clarify before proceeding when:
- QuantiFERON kit unavailable or wrong tube type on tray
- Incubator unavailable and laboratory courier deadline will be missed
- Duplicate IGRA recently resulted — confirm need for repeat draw
- Patient has cough or fever but only outpatient follow-up is planned without prescriber review
- Biologic infusion scheduled before TB evaluation completes
- Recent positive IGRA with no documented chest imaging or public health pathway
Reading IGRA Results With Symptoms and TB Risk
Integrate IGRA results with symptoms, chest imaging, exposure history, immunosuppression plan, and prior TB treatment. A negative result on a valid specimen lowers infection likelihood but may not exclude disease when immunosuppressed or recently exposed. A positive result always requires next-step evaluation — not automatic isolation unless clinical suspicion supports active pulmonary TB.
| Clinical context | IGRA pattern | Nursing focus |
|---|---|---|
| Pre-biologic screen, asymptomatic | Positive IGRA | Notify prescriber; defer biologic until TB evaluation authorized; arrange chest imaging per orders |
| Cough or fever with new positive IGRA | Positive with symptoms | Airborne precautions per policy; expedite imaging and sputum studies as ordered |
| Immunosuppressed patient, high suspicion | Negative IGRA | Do not dismiss symptoms; notify prescriber — repeat or alternate testing may be indicated |
| Invalid specimen flag from laboratory | No valid result | Repeat collection per kit insert; do not chart infection status from rejected sample |
On a small screen, swipe or scroll sideways to see the full table.
Reference ranges, critical values, and protocols may vary by laboratory, institution, patient population, and testing method. Always follow local policy and the reporting laboratory’s reference range.
IGRA Collection Tubes, Mixing, and Incubation Validity
QuantiFERON-TB Gold Plus is a time- and technique-sensitive assay. Manufacturer kit instructions reviewed for this page emphasize antigen-coated tubes, immediate mixing after draw, room-temperature hold until incubation, and upright 37°C incubation for 16–24 hours within the post-collection window specified in the kit insert and local laboratory protocol.
| Pre-analytic step | Why it matters | Nursing action |
|---|---|---|
| Fill each kit tube to indicator line | Underfill or overfill can invalidate results per manufacturer instructions | Use needle and holder; purge butterfly line if required; replace inadequate tubes immediately |
| Mix immediately after draw | Antigens are dried on tube walls and must contact whole blood | Invert or shake per kit insert (commonly ten times — avoid over-vigorous mixing) |
| Room-temperature hold | Tubes are designed for controlled ambient hold before incubation | Do not refrigerate unincubated tubes unless laboratory protocol explicitly directs |
| 37°C incubation timing | Delayed incubation beyond kit limits can reject specimens | Start onsite incubation or meet courier deadline per institutional protocol |
| Upright incubation | Gel barrier and cell viability depend on proper tube position | Place tubes upright in rack off incubator floor as directed in kit handbook |
On a small screen, swipe or scroll sideways to see the full table.
Tube Timing, Incubation, and False Reassurance at the Bedside
| Bedside point | Nursing note |
|---|---|
| Kit not routine tubes | Standard CBC tubes cannot substitute for QuantiFERON kit tubes |
| Single visit advantage | IGRA avoids TST return visit — but only if incubation logistics succeed |
| BCG history | IGRA generally preferred when BCG complicates skin test — still interpret with clinical context |
| Biologic hold communication | Positive IGRA before TNF inhibitor needs prescriber-led hold — nurses do not independently cancel infusion without order |
| Language matters | Say “infection detected” not “you have active TB” until evaluation completes |
| Evaluate outcomes | Reassess cough, imaging results, and authorized infusion status after TB pathway steps — stable vitals alone do not clear positive IGRA |
On a small screen, swipe or scroll sideways to see the full table.
The clarify / hold rule
Clarify before proceeding when:
- Kit tubes are unavailable, expired, or wrong type for the ordered IGRA
- Incubator or courier window cannot be met — invalid results likely
- Positive or indeterminate IGRA with biologic therapy still scheduled without prescriber review
- Respiratory symptoms present but airborne precautions or imaging not addressed
- Laboratory rejects specimen for underfill, hemolysis, or timing — repeat plan unclear
- Patient received false reassurance that IGRA replaces all further TB evaluation
Why Quantiferon TB Gold is Ordered
QuantiFERON-TB Gold IGRA is ordered when clinicians need a blood-based test for M. tuberculosis infection, especially when a single-visit assay is preferred or BCG history makes skin-test interpretation difficult.
| Clinical Indication | What the Test Answers | Nursing Rationale |
|---|---|---|
| Latent TB infection (LTBI) screening | Has the patient been infected with TB bacteria even without active disease symptoms? | public health guidance and standard clinical references list IGRA among tests used to detect TB infection; positive results prompt evaluation for LTBI treatment eligibility versus active disease workup. |
| Pre-biologic or immunosuppressive therapy screening | Is TB infection ruled out or identified before TNF inhibitors or other immunosuppression? | Rheumatology and oncology pathways commonly require TB screening before biologics; positive IGRA must be evaluated before starting therapy per prescriber and specialty protocol. |
| TB contact or outbreak investigation | Was there significant exposure to a person with infectious TB? | Public health and CDC guidance support IGRA or skin testing after exposure with timing and repeat testing per institutional protocol — not a single universal schedule in reviewed references. |
| Evaluation when active pulmonary TB is suspected | Does immune sensitization support the broader TB disease workup? | pulmonary TB evaluation may include IGRA such as QFT-Gold alongside imaging and sputum studies — IGRA alone cannot confirm or exclude active disease. |
Contraindications and Precautions
There are no absolute contraindications to IGRA blood collection when the test is clinically indicated. Nursing focus is valid kit use, correct timing, and safe communication — not withholding indicated TB screening.
- Positive IGRA with fever, productive cough, hemoptysis, night sweats, or weight loss — evaluate for active TB and airborne precautions per facility policy.
- Patient scheduled to start biologic or high-dose immunosuppression with positive or indeterminate IGRA and no documented TB evaluation.
- Suspected invalid specimen (underfilled tubes, missed incubation window, wrong tubes) with clinical TB concern — repeat collection per laboratory and prescriber direction.
- Positive IGRA indicates TB infection but not necessarily active disease — chest imaging and symptom assessment still required per public health guidance and standard clinical references.
- Indeterminate or borderline results — may reflect immunosuppression, processing error, or insufficient mitogen response; repeat testing per protocol.
- Negative IGRA in severely immunocompromised patients may not exclude infection — correlate with HIV status, medicines, and symptoms.
- Positive IGRA with respiratory symptoms, hypoxia, or hemodynamic instability suggesting active TB.
- Indeterminate IGRA before planned biologic therapy without prescriber review.
- Laboratory flags invalid or hemolyzed specimen with pending immunosuppressive start date.
Patient Preparation
Preparation centers on kit readiness, patient identification, medicine and exposure history, and realistic teaching about what IGRA can and cannot show — not fasting for standard IGRA draws.
Pre-test checkspublic health guidance and clinical references note immunosuppressive therapy — including corticosteroids, TNF inhibitors, and chemotherapy — may reduce IGRA sensitivity. Document current medicines for prescriber review; do not hold immunosuppressants or biologics unless explicitly ordered. If LTBI treatment such as isoniazid or rifampin is already in progress, note this for interpretation context per infectious disease or primary care plan.
Performance — nursing procedure guide
This page is a Tests & Diagnostics guide for Quantiferon TB Gold. It emphasizes why the test is ordered, how to interpret results, when to escalate, and preparation factors that affect validity — not step-by-step performance technique (those live under Nursing Procedures when available).
Step-by-step technique, supplies, infection prevention, and immediate post-procedure monitoring for this test are covered in:
Use the Patient preparation, Results and interpretation, and Nursing responsibilities sections on this page for order verification, pre-analytic checks, result follow-up, critical-value escalation, and documentation.
Result follow-up at a glance
Nursing workflow on this page — from order to safe action on results:
Results and Interpretation
QuantiFERON-TB Gold IGRA is reported qualitatively. TB blood test results as positive, negative, or borderline (indeterminate). A negative result suggests no detected TB infection on that sample; a positive result means infection is likely and further evaluation is needed to distinguish LTBI from active disease. Indeterminate results require repeat collection or alternate testing per laboratory comment and prescriber plan.
Reference ranges, critical values, and protocols may vary by laboratory, institution, patient population, and testing method. Always follow local policy and the reporting laboratory’s reference range.
| Result | Range / Finding | Clinical Meaning | Nursing Action |
|---|---|---|---|
| Negative / not detected | Negative / not detected on IGRA | No evidence of TB infection detected on this valid specimen at time of testing | Document result; continue routine TB risk screening intervals per policy; if symptoms suggest active TB despite negative IGRA, notify prescriber — immunosuppression may cause false-negative results |
| Equivocal / borderline | Indeterminate / borderline IGRA | Laboratory could not classify infection status — may reflect processing error, insufficient mitogen control response, or immunosuppression per kit interpretation rules | Notify prescriber; arrange repeat IGRA or alternate TB testing per protocol; delay high-risk immunosuppression until clarified when ordered |
| Positive / elevated | Positive IGRA | TB infection detected — latent or active disease possible; does not by itself define infectiousness or lung involvement | Notify prescriber and infection prevention/public health per policy; arrange chest imaging and symptom review; implement airborne precautions when active pulmonary TB is suspected; support LTBI or active TB treatment orders as authorized |
| Not applicable / below detection limit | Not applicable — IGRA is qualitative, not a low numeric level | Not applicable | Not applicable |
Positive IGRA With Respiratory Symptoms and Isolation Triggers
IGRA does not use numeric critical-value thresholds in most laboratories. Nursing urgency is driven by positive or indeterminate results paired with symptoms, imminent immunosuppression, invalid specimens, or public health mandates — not by qualitative positivity alone in an asymptomatic screen.
| Critical Finding | Threshold / Value | Immediate Action |
|---|---|---|
| Positive IGRA with cough, fever, or night sweats | Symptoms suggesting active pulmonary TB with newly positive or previously untreated IGRA | Initiate airborne isolation and mask use per institutional TB policy; notify prescriber and infection prevention; arrange chest imaging and sputum studies as ordered |
| Positive IGRA before scheduled biologic infusion | Biologic or high-dose steroid start within 24–48 hours without documented TB evaluation | Hold therapy only per prescriber order; urgently notify rheumatology or oncology team and infectious disease per protocol |
| Invalid specimen with clinical TB concern | Underfilled tubes, missed incubation window, or laboratory rejection with ongoing symptoms | Repeat collection per kit insert and laboratory; do not reassure based on absent result from invalid sample |
Escalate according to facility policy when IGRA is positive or indeterminate with respiratory symptoms, before starting major immunosuppression, when specimens are invalid but suspicion remains high, or when the patient deteriorates while TB evaluation is pending.
Factors Affecting Results
IGRA accuracy depends on valid specimen handling and patient immune status. Nurses reduce harm by documenting collection quality and avoiding single-result conclusions when factors below apply.
- Rare false-positive IGRA in low-prevalence populations — prescriber and public health interpretation per CDC guidance
- Positive IGRA interpreted as active contagious TB without symptom and imaging correlation
- Starting LTBI treatment teaching before prescriber confirms latent versus active disease plan
- Severe immunosuppression or HIV with low CD4 — reduced sensitivity per public health guidance clinical considerations
- Very early after TB exposure before sensitization develops — repeat testing may be indicated per protocol
- Invalid specimen from underfilled tubes, delayed incubation, or improper mixing — apparent negative may be unreliable
- Underfilled or overfilled QuantiFERON tubes — invalid or skewed results
- Delayed incubation beyond kit time limits — specimen rejection or indeterminate report
- Immunosuppressive medicines or acute febrile illness — may reduce interferon-gamma response
QuantiFERON-TB Gold IGRA detects TB infection but cannot by itself distinguish latent infection from active TB disease, prove current infectiousness, or replace chest imaging and microbiologic studies when pulmonary TB is suspected. It does not monitor treatment response routinely. Results must be interpreted with symptoms, exposure history, radiography, and public health guidance. Nurses do not independently classify patients as non-infectious based on IGRA alone.
Nursing Responsibilities
Nursing care spans kit-based blood collection quality, incubation handoff, result notification, airborne precaution coordination when active TB is suspected, and balanced teaching about LTBI versus active disease pathways.
Before the TestDocumentation
Documentation should capture kit lot if required locally, tube fill and mixing, incubation time, qualitative result, notifications, isolation orders, and patient teaching — without charting active TB disease from a positive IGRA alone.
“QuantiFERON-TB Gold Plus collected 09:15 — four kit tubes filled to indicator line, mixed ×10 per kit insert, incubated onsite 09:35. Indication: pre-adalimumab LTBI screen. Result 14:20: positive IGRA. Patient reports dry cough two weeks, afebrile today. Dr. Chen notified 14:28; airborne isolation initiated per TB policy; chest X-ray ordered stat; employee health notified per protocol. Patient taught that positive infection test requires further evaluation — not a final diagnosis of active TB.”
- Indication, exposure history, and immunosuppressive medicine list
- Kit tube fill, mixing, incubation start time, and transport
- Qualitative IGRA result with laboratory comment
- Symptoms, isolation status, and imaging or sputum orders
- Prescriber and public health notification with read-back if required
- Patient teaching on next steps and authorized LTBI or active TB plan
Patient and Family Education
Use plain language aligned with public health guidance and standard clinical references: the test checks whether your immune system recognizes TB bacteria. Avoid stigma and avoid definitive active-TB labeling at the bedside.
Quantiferon TB Gold NCLEX practice questions
Practice NCLEX-style clinical judgment focused on Quantiferon TB Gold safety and nursing judgment. Use the case tabs (orders, results, assessment, nursing notes), then answer eight Next Gen–style items (including an ordered workflow step) and evaluate outcomes with the answer key.
Select a tab to view orders, results, assessment, and nursing note details for this case.
- Order: QuantiFERON-TB Gold Plus IGRA — rheumatology infusion unit
- Indication: Pre-adalimumab TB screen; patient reports two-week dry cough
- Timing: Blood drawn 08:40; tubes incubated 08:55; result positive IGRA at 13:10
- Related orders: Adalimumab infusion scheduled 16:00; chest X-ray ordered stat — not yet performed
- Result: QuantiFERON-TB Gold Plus: positive; Nil control within expected range per lab comment
- Trend / prior value: Prior IGRA two years ago negative; no documented LTBI treatment since
- Pending tests: Chest X-ray pending; infectious disease consult not yet contacted; infusion still on schedule
- Vital signs: Temp 37.2°C, HR 88/min, BP 122/76 mmHg, RR 16/min, SpO₂ 98% on room air
- Symptoms: Dry cough two weeks, mild fatigue, no hemoptysis or night sweats reported today
- Focused assessment: Lungs clear to auscultation; no visible respiratory distress; surgical mask available at bedside
- Preparation notes: Four kit tubes filled and mixed per protocol; patient told positive IGRA means infusion can proceed as planned
- Collection events: Venipuncture one attempt; tubes upright in incubator within 15 minutes of draw
- Teaching gaps / safety concerns: Positive IGRA with cough before biologic; chest imaging pending; inaccurate reassurance about infusion
Answer key & rationale
Frequently Asked Questions
FAQ
What is QuantiFERON-TB Gold?
QuantiFERON-TB Gold is a brand of interferon-gamma release assay (IGRA) — a TB blood test that measures T-cell response to TB antigens in specialized collection tubes. Many laboratories now use QuantiFERON-TB Gold Plus with four tubes. It screens for M. tuberculosis infection, often for latent TB, and supports broader TB evaluation when clinically indicated.
Does a positive QuantiFERON result mean active TB?
Not necessarily. standard clinical references and public health guidance state a positive TB blood test shows TB infection but additional evaluation — such as symptom review, chest imaging, and sometimes sputum studies — is needed to determine whether disease is active.
Do patients need to fast before QuantiFERON testing?
Usually no special preparation is required for IGRA blood testing. Follow local policy if other fasting labs are collected at the same visit.
How is QuantiFERON different from a TB skin test?
The tuberculin skin test (PPD/Mantoux) requires an intradermal injection and a return visit for reading. IGRA requires a single blood draw into kit tubes. IGRA is generally not affected by BCG vaccination the way skin tests can be, but test choice follows institutional and public health guidance.
What can cause an indeterminate QuantiFERON result?
Indeterminate or borderline results may reflect immunosuppression, specimen handling errors (underfilled tubes, delayed incubation, inadequate mixing), or insufficient mitogen control response. Repeat testing or alternate TB screening per laboratory comment and prescriber plan.
When should nurses escalate QuantiFERON results?
Escalate according to facility policy when IGRA is positive or indeterminate before immunosuppressive or biologic therapy, when respiratory symptoms suggest active TB, when specimens are invalid but clinical suspicion remains, or when isolation and public health requirements are not yet met.
Can QuantiFERON be used during pregnancy or before biologics?
IGRA is commonly used in pre-biologic and many prenatal screening pathways per prescriber and specialty guidelines. Positive results require evaluation before starting immunosuppression. Pregnancy-specific protocols vary — follow obstetric, rheumatology, and infectious disease orders.
References
References
-
Centers for Disease Control and Prevention. Testing for Tuberculosis. CDC.https://www.cdc.gov/tb/testing/index.html
-
U.S. National Library of Medicine. Tuberculosis Screening. MedlinePlus Medical Test.https://medlineplus.gov/lab-tests/tuberculosis-screening/
-
Centers for Disease Control and Prevention. Clinical Overview of Latent Tuberculosis Infection. CDC.https://www.cdc.gov/tb/topic/treatment/ltbi.htm
-
Lewinsohn DM; Leonard MK; LoBue PA; et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis. 2017.https://www.cdc.gov/tb/publications/guidelines/pdf/Clinical_Diagnosis_TB_508.pdf
-
World Health Organization. WHO consolidated guidelines on tuberculosis: Module 3: Diagnosis — Tests for TB infection. WHO; 2022.https://www.who.int/publications/i/item/9789240043516
-
U.S. National Library of Medicine. Pulmonary tuberculosis. MedlinePlus Medical Encyclopedia.https://medlineplus.gov/ency/article/000077.htm
-
QIAGEN. QuantiFERON-TB Gold Plus Blood Collection Tubes — Instructions for Use. Manufacturer kit handbook (FDA-cleared collection system).https://www.qiagen.com/us/tb-testing/what-is-quantiferon/how-does-qft-work
-
U.S. National Library of Medicine. Acid-Fast Bacillus (AFB) Tests. MedlinePlus Medical Test.https://medlineplus.gov/lab-tests/acid-fast-bacillus-afb-tests/
Editorial Standards & Medical Review
About the author: Sid A. Abdala Balal, RN, writes evidence-based nursing education focused on diagnostic safety, clinical interpretation, and bedside nursing judgment.
Medical review: This guide is reviewed by Dr. Adam Sayedi, MD, for clinical accuracy, diagnostic safety, and alignment with current standards for Quantiferon TB Gold.
Policies: Medical Review Process · Editorial Policy · Correction Policy